anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
Red blood cell distribution width (RDW) is a measure of the range of variation of red blood cell (RBC) volume. The RDW-SD (Standard deviation ) is an actual measure of size. Normal reference range of RDW-SD in adult human is 39-46 fL .Liver plays an important role in removing body toxins which affects RBCs ,so liver cirrhosis may affects the RDW. Cirrhosis is a chronic degenerative disease in which irreversible scarring of the liver occurs. It leads to liver failure. Child's score is used as an indicator for liver cell function Portal hypertension is an increase in the blood pressure within the portal venous system .Obstruction to blood flow that occurs in liver due to fibrosis and regenerating nodules reduce flow from the portal veins into the hepatic veins. It also impedes hepatic artery flow from the branches that feed into the sinusoids. This increase in arterial resistance leads to an increase in arterial flow into the portal vein via producing a new anastamosis. The net result of that is an increase in portal vein pressure and dilatation of portal vein. Direct measurement of portal pressure is invasive, inconvenient, and clinically impractical. The Hepatic Venous Pressure Gradient (HVPG) is used to measure portal pressure .Recently, portal vein diameter is used as indicator for portal hypertension .
PURPOSE: To obtain a composition containing a peptide having fibroblast cell growth factor action and a cationic polyelectrolyte and useful for treatment of wound. CONSTITUTION: This composition contains a peptide having biological action of a fibroblast cell growth factor (referred to as FGF) and a cationic high polyelectrolyte (e.g. polyamine) as active ingredients. The peptide is used in a concentration of 0.1ng to 500μg/ml and the cationic polyelectrolyte is used in a concentration of 1μg to 500μg/ml. In the peptide having FGH action, the biological activity is not influenced upon FGF receptor of a cell membrane by the non-specific bond. The composition is useful for treatment of skin damage of bed sore, diabetic gangrene, arterial and venous hemostasis, etc., burn, wound from mucosal ulcer and injury, wound, etc., due to operation.
PCT No. PCT/CA90/00306 Sec. 371 Date Jul. 3, 1991 Sec. 102(e) Date Jul. 3, 1991 PCT Filed Sep. 18, 1990 PCT Pub. No. WO91/04058 PCT Pub. Date Apr. 4, 1991A pharmaceutical composition is provided comprising: (1) an agent selected from a medicinal agent and a therapeutic agent and combinations thereof in a therapeutically effective amount to treat a disease or condition in humans who will benefit from the treatment with the agent; and (2) hyaluronic acid and/or pharmaceutically acceptable salts thereof and/or fragments, and subunits of hyaluronic acid, characterized in that said composition (a) is in a dosage form which is suitable for administration in humans; and (b) is in a form in which (i) component (1) is in an effective dosage amount to treat said disease or condition by penetration at the site to be treated; and (ii) component (2) is immediately available to transport component (1) at the site to be treated, and which component (2) is in an effective non-toxic amount to facilitate the transport of component (1) upon administration, through the tissue including scar tissue, at the site to be treated and through the cell membranes or the individual cells to be treated, wherein said amount of component (2) is sufficient to provide a dosage greater than 10 mg/70 kg person of component (2).
Roux-en- Y gastric bypass (RYGB) is the most popular bariatric procedure and it has been associated with improvements in glycemic control and cognitive function. It works by decreasing the amount of food you can eat at one sitting and by changing the hormones released at the bottom of the stomach and duodenum.we propose that RYGB is a model of chronic elevation of GLP-1 providing an opportunity to explore relationship between changes in the circulating hormone and brain glucose metabolism, cognitive function and neuroplasticity.
The present invention provides hydrophilic polyurethane pressure-sensitive adhesive and a preparation method thereof. In polyurethane polyol prepared from polyurethane which is formed from at least three kinds of polymer polyol by the irregular bonding of diisocyanate, low molecular diamine or a polymer thereof, one kind of polymer polyol is polyglycol or a derivative thereof; one kind of polymer polyol is hydrophobic macromolecular dibasic alcohol; one kind of polymer polyol is macromolecular polyol containing at least three hydroxy groups. Butanone is adopted as a solvent. First, the diisocyanate and the macromolecular polyol are condensed and polymerized to form a prepolymer with a-NCO group; then, polyurethane is prepared from the low molecular diamine or the polymer thereof by chain propagation. The hydrophilic polyurethane pressure-sensitive adhesive is characterized in that the hydrophilic polyurethane pressure-sensitive adhesive has the performance of hydrophilicity, repeated pasting performance, favorable skin compatibility, etc. The defects of hydrophobic pressure-sensitive adhesive are overcome. The pressure-sensitive adhesive can be independently used, or can be physically combined with one or multiple components of a water-soluble polymer, a surfactant, hydrogel, a nanometer particle or a micelle to be used as medical and medicinal pressure-sensitive adhesive.
LYTGOBI can cause hyperphosphatemia leading to soft tissue mineralization, calcinosis, nonuremic calciphylaxis, and vascular calcification. Increases in phosphate levels are a pharmacodynamic effect of LYTGOBI [see Clinical Pharmacology (12.2)]. Among 318 patients who received LYTGOBI across clinical trials [see Adverse Reactions (6.1)], hyperphosphatemia was reported in 88% of patients based on laboratory values above the upper limit of normal. The median time to onset of hyperphosphatemia was 5 days (range 3-117). Phosphate binders were received by 77% of patients who received LYTGOBI.

Monitor for hyperphosphatemia throughout treatment. Initiate a low phosphate diet and phosphate lowering therapy when serum phosphate level is ≥5.5 mg/dL. For serum phosphate levels >7 mg/dL, initiate or intensify phosphate lowering therapy and dose reduce, withhold, or permanently discontinue LYTGOBI based on duration and severity of hyperphosphatemia [see Dosage and Administration (2.3)].
NEW MATERIAL:An anti-inflammatory analgesic compound exhibiting infrared absorption spectrum having characteristic absorption at 3120, 3020, 1480, 1400 and 950cm<-1> and free from characteristic absorption at 1640 and 1540cm<-1>. The compound has the following properties. (A) Negative to staining test on a compound containing large amount of glycoproteins, heparin, chondroitinsulfuric acid, polysaccharide and other hydrocarbons using a periodic acid Schiff reaction reagent (PAS), (B) negative to color reaction with anthrone reagent, (C) negative to color reaction on uronic acid by carbazolesulfate process, etc. USE:An anti-inflammatory agent and analgesic agent. PREPARATION:A liquid poison is collected from an ant of species triplarinus, genus Pseudomirmex and diluted with an aqueous solution. After removing foreign materials, the solution is passed through a column for hydrophilic vinyl resin adsorption chromatography. The toxic extract is eluted from the column and passed through a column for cation exchange chromatography.
Obesity is characterized by a chronic inflammatory state, often linked with elevated oxidative stress and mitochondrial dysfunction. While physical exercise can trigger inflammatory responses due to muscle damage, it also promotes significant bodily adaptations, particularly in body composition, physical fitness, and skeletal muscle tissue, including enhanced mitochondrial dynamics. Moderate hypoxia, when combined with exercise, further amplifies these benefits by increasing the expression of genes related to mitochondrial biogenesis, GLUT1 expression, and angiogenesis. Previous findings suggest that high-intensity physical activity not only improves cardiorespiratory capacity and alters body composition but also significantly elevates inflammation. Consequently, taurine, a supplement known for its anti-inflammatory properties and ability to reduce oxidative stress, should be considered to mitigate these issues and optimize the benefits of exercise and hypoxia. Based on these premises, it is hypothesized that the combination of taurine supplementation with physical training under recovery hypoxia may reduce the significant rise in pro-inflammatory cytokines, thereby enhancing the potential benefits of exercise and moderate hypoxia.
UNLABELLED: Altered gut microbiota and metabolites are important for non-alcoholic fatty liver disease (NAFLD) in children. We aimed to comprehensively examine the effects of gut metabolites on NAFLD progression. We performed integrative metabolomics (untargeted discovery and targeted validation) analysis of non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and obesity in children. Fecal samples were collected from 75 subjects in the discovery cohort (25 NAFL, 25 NASH, and 25 obese control children) and 145 subjects in an independent validation cohort (53 NAFL, 39 NASH, and 53 obese control children). Among 2,491 metabolites, untargeted metabolomics revealed a complete NAFLD metabolic map containing 318 increased and 123 decreased metabolites. Then, machine learning selected 65 important metabolites that can distinguish the severity of the NAFLD. Furthermore, precision-targeted metabolomics selected 5 novel gut metabolites from 20 typical metabolites. The functionality of candidate metabolites was validated in hepatocyte cell lines. In the end, this study annotated two novel elevated pathogenic metabolites (dodecanoic acid and creatinine) and a relationship between depleted protective gut microbiota (Butyricicoccus and Alistipes), increased inflammation (IL-1β), lipid metabolism (TG), and liver function (ALT and AST). This study demonstrates the role of novel gut metabolites (dodecanoic acid and creatinine), as the fatty acid metabolism regulator contributing to NAFLD development through its influence on inflammation and liver function.
IMPORTANCE: Altered gut microbiota and metabolites are a major cause of non-alcoholic fatty liver disease (NAFLD) in children. This study demonstrated a complete gut metabolic map of children with NAFLD, containing 318 increased and 123 decreased metabolites by untargeted metabolomic. Multiple validation approaches (machine learning and targeted metabolomic) selected five novel gut metabolites for targeted metabolomics, which can distinguish NAFLD status and severity. The gut microbiota (Butyricicoccus and Alistipes) and metabolites (creatinine and dodecanoic acid) were novel biomarkers associated with impaired liver function and inflammation and validated by experiments of hepatocyte cell lines. The data provide a better understanding of the importance of gut microbiota and metabolite alterations in NAFLD, which implies that the altered gut microbiota and metabolites may represent a potential target to prevent NAFLD development.
Dysregulation of histone methyltransferase SET and MYND domain-containing protein 2 (SMYD2) has been correlated with human developmental disorders and cancers. This research aims to investigate the roles of SMYD2 and its interacted molecules in pancreatic adenocarcinoma (PAAD). Two PAAD-related gene expression datasets were downloaded to screen key molecules involved in tumor progression. SMYD2 was expressed at high levels in PAAD tissues and cells. SMYD2 silencing suppressed while its overexpression promoted proliferation, invasiveness, migration, apoptosis resistance, and cell cycle progression of PAAD cells. Target molecules of SMYD2 were predicted by online tools and validated by chromatin immunoprecipitation and luciferase assays. SMYD2 catalyzed H3K36me2 modification at the promoter region of MNAT1 component of CDK activating kinase (MNAT1), to promote its transcription. MNAT1 was correlated with an unfavorable clinical outcome of PAAD patients. Alteration of MNAT1 alone also affected the malignant behavior of PAAD cells. Moreover, MNAT1 overexpression in cells rescued the malignant phenotype of cells suppressed by SMYD2 silencing. MNAT1 activated the phosphatidyl inositol 3-kinase/protein kinase B (PI3K/AKT) signaling. In vivo, SMYD2 silencing decreased the growth rate and weight of xenograft tumors in nude mice. Overall, this paper demonstrates that SMYD2-mediated MNAT1 upregulation is linked to PAAD tumorigenesis via PI3K/AKT pathway activation.
The invention discloses a drug for treating epilepsy, belonging to the Chinese traditional medicine field. The drug is prepared by Cornu Saigae Tataricae, Ramulus Uncariae cum Uncis, Folium Mori, Radix Paeoniae Alba, Radix Rehmanniae, Poria, Indian Bread With Hostwood, Radix Salviae Miltiorrhizae, Radix Glycyrrhizae, Bulbus Fritillariae Unibracteatae and Caulis Bambusae In Taeniam in a certain weight proportion. The application method of the invention is that the raw materials are mixed and placed in an earthen pot, water of certain quantity is added into the pot to ensure the raw materials to be fully infused; the raw materials is first boiled on strong fire and then decocted on slow fire for half an hour, the liquid is filtered out; water with certain quantity is added into the drugs and decocted for half an hour, the liquid is filtered out. The liquid filtered in two times is mixed and cooled completely; the liquid is taken respectively half an hour before the breakfast and two hours after the dinner. With the main efficacies of promoting qi circulation and opening qi depression, calming the nerves and restoring consciousness, the invention can nourish the brain, relieve convulsion and calming down wind, can effectively restrain epilepsy and has evident therapy effect on severe and slight paroxysm, psychomotor paroxysm, limited paroxysm or complex part paroxysm and persistent state of epilepsy. The invention has the advantages of strong potency of drug, good efficacy, uneasy recurrence and accurate therapy effect.
In a double-blind, placebo-controlled clinical study, 209 otherwise healthy subjects 18 years and older with genital/perianal warts were treated with ALDARA Cream or vehicle control 3 times per week for a maximum of 16 weeks. The median baseline wart area was 69 mm 2(range 8 to 5525 mm 2). Subject accountability is shown in Figure 1. 

*The other subjects were either lost to follow-up or experienced recurrences.

Data on complete clearance are listed in Table 14. The median time to complete wart clearance was 10 weeks.
PURPOSE: Sepsis has a high incidence and a poor prognosis. Early recognition is important to facilitate timely initiation of adequate care. Sepsis screening tools, such as the (quick) Sequential Organ Failure Assessment ((q)SOFA) and National Early Warning Score (NEWS), could help recognize sepsis. These tools have been validated in a general immunocompetent population, while their performance in immunocompromised patients, who are particularly at risk of sepsis development, remains unknown.
METHODS: This study is a post hoc analysis of a prospective observational study performed at the emergency department. Inclusion criteria were age ≥ 18 years with a suspected infection, while ≥ two qSOFA and/or SOFA criteria were used to classify patients as having suspected sepsis. The primary outcome was in-hospital mortality.
RESULTS: 1516 patients, of which 40.5% used one or more immunosuppressives, were included. NEWS had a higher prognostic accuracy as compared to qSOFA for predicting poor outcome among immunocompromised sepsis patients. Of all tested immunosuppressives, high-dose glucocorticoid therapy was associated with a threefold increased risk of both in-hospital and 28-day mortality.
CONCLUSION: In contrast to NEWS, qSOFA underestimates the risk of adverse outcome in patients using high-dose glucocorticoids. As a clinical consequence, to adequately assess the severity of illness among immunocompromised patients, health care professionals should best use the NEWS.
OBJECTIVE: Tolvaptan is a vasopressin V2 receptor antagonist that is commonly prescribed to alleviate edema associated with renal diseases. However, the clinical benefits of tolvaptan in chronic kidney disease (CKD) remain unclear. This study aimed to evaluate the effectiveness of tolvaptan in managing edema caused by CKD.
MATERIALS AND METHODS: The efficacy and treatment regimen of tolvaptan were assessed in a cohort of 96 patients with renal edema and CKD. During the treatment, the patients' creatinine (CR), uric acid (UA), and estimated glomerular filtration rate (eGFR) were monitored as important indicators of kidney function. Coagulation-associated molecules including fibrinogen, D-dimer, and fibrin degradation products (FDPs) were measured. Electrolyte disorders and acute kidney injury were closely monitored. Tolvaptan was administered at a daily dose of 7.5 mg, and 30 mg of edoxaban was administered to manage deep vein thrombosis.
RESULTS: During the course of tolvaptan therapy, the eGFR of the patients was not declined. Edema was eliminated in 82.18% of patients. Proteinuria was reduced in the patients (p < 0.05). There were no significant changes in serum sodium levels throughout treatment, and no significant difference was observed in blood volume between the end of treatment and baseline levels. Importantly, acute kidney injury did not occur, and renal edema and deep vein thrombosis were successfully treated.
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.
Participants in this group will undergo FIFA 11+ protocol along with additional Core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge will be given. Each exercise plan will be progressively increased.
Infection with HCV is common in patients infected with HIV owing to similar routes of transmission. The cellular immunosuppression caused by HIV infection appears to lead to an increased HCV plasma load, more progressive liver disease, and, in patients with chronic hepatitis C, increased mortality. Ribavirin treatment combined with IFN has shown improved sustained virologic response rates over IFN monotherapy. PEG-IFN, a chemically modified formulation of IFN, circulates for a much longer time in the blood than the parent compound. Pharmacokinetic and pharmacodynamic data suggest that PEG-IFN injected weekly would have the potential for superior efficacy as compared with IFN injected 3 times per week. The efficacy and safety profiles of combination therapy with PEG-IFN and ribavirin are not well known. This study will compare combination therapy consisting of PEG-IFN and ribavirin with that of IFN and ribavirin.

Patients are stratified according to HCV genotype and CD4 count and viral load, then randomized to either Arm A (IFN plus ribavirin) or Arm B (PEG-IFN plus ribavirin). Patients receive up to 48 weeks of treatment. Virologic response is assessed at Week 24 and a decision to continue or discontinue treatment is made. If a virologic response is shown at Week 24, the patient continues treatment for an additional 24 weeks. If no virologic response is observed, then the histologic response is assessed by a liver biopsy. If biopsy shows a histologic response is present, treatment is continued for 24 weeks. If biopsy shows no histologic response, treatment is discontinued. \[AS PER AMENDMENT 07/20/01: Patients with virologic response who discontinue after Week 24 will have liver biopsy at time of discontinuation. Patients with no virologic response continuing study treatment after having a liver biopsy within 2 weeks of Week 24, who also demonstrate histologic response and decide to discontinue after Week 24, are strongly encouraged to have a 2nd liver biopsy at the end of treatment. Patients with no virologic response who discontinue after Week 24 will not have liver biopsy at time of discontinuation.\] Physical examinations are done regularly and blood samples collected for routine laboratory tests, confidential genetic testing, and to measure HCV and HIV-1 plasma viral loads. Women able to become pregnant have regular pregnancy tests. All patients are followed for an additional 24 weeks after treatment discontinuation.

Patients may enroll in 1 or none of the following substudies: A5091s, Hepatic C Viral Kinetics in Subjects Co-infected with Human Immunodeficiency Virus-1 (HIV-1) and Hepatitis C Virus Genotype 1 (HCV-1); \[AS PER AMENDMENT 07/20/01: The following text has been deleted: or A5092s, Evaluation of the Effects of Ribavirin on Zidovudine (ZDV) or Stavudine (d4T) Triphosphate Formation\] \[AS PER AMENDMENT 07/20/01: Substudy A5092s, Evaluation of the Effects of Ribavirin on Zidovudine (ZDV) or Stavudine (d4T) Triphosphate Formation is now a stand-alone study.\]
Triple-negative breast cancer (TNBC) is known to have the worst outcome compared to the other forms of breast cancer. Moreover, molecular markers identified basal-like breast cancer (BLBC) phenotypes to be also related to a worse prognosis. In this study, we evaluated by immunohistochemistry (IHC) the prognostic significance of combining Cytokeratin-19 (CK19), E-cadherin, and Ki-67 tissue expression in triple-negative breast cancer (TNBC) cases presenting a basal-like (BLBC) or a non-basal-like (n-BLBC) phenotype to improve the selection and the monitoring of BC patients with a more aggressive outcome. Herein, when compared to n-BLBC, patients with BLBC showed a positive correlation with lymph node metastasis occurrence and lower survival rates. Immunohistochemistry analysis revealed significantly lower E-cadherin prevalence and higher prevalence of both CK19 and Ki-67 in BLBC when compared to n-BLBC. Spearman correlation showed that E-cadherin is negatively and significantly correlated to CK19 and Ki-67 expressions. Moreover, in BLBC, expressing both CK19 and Ki-67 combined with E-cadherin loss was associated with the worst relapse-free and overall survival. In conclusion, TNBC/BLBC phenotypes simultaneously losing E-cadherin and overexpressing CK19 and Ki-67 markers are the most aggressive forms. This combined analysis could be a predictive marker of poor prognosis.
A mobile System is disclosed that uses biometric identification to identify an injured person, provides an immediate warning of a special or medical condition, and can transmit that data to the hospital along with additional photos and video of the injury. This provides emergency rooms with access to the patient's medical records, history of the patient's medical conditions, real-time photographs which better prepare the medical staff to identify the incoming patent prior to the patient arriving at the hospital. Additional embodiments involve Law Enforcement uses where criminal, missing persons and wanted persons' data are used for identification. Military uses involve the use of data of military persons of concern. Medical fraud prevention documents medical transport, patient identity, verification of medical cards; and physician services documentation. This invention can save the medical services community billions of dollars and prevent administrative mistakes which can result in injury and/or loss of life.